Genentech
A Member of the Roche Group
Access Solutions

for TECENTRIQ® (atezolizumab)

SAMPLE CODING

Hepatocellular Carcinoma (HCC)

TYPE	CODE		DESCRIPTION
Diagnosis: ICD-10-CM	C22.0		Liver cell carcinoma
	C22.8		Malignant neoplasm of liver, primary, unspecified as to type
Drug: HCPCS	J9022		Injection, atezolizumab, 10 mg
HCPCS: Modifier*	JZ		Zero drug amount discarded/not administered to any patient
Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.	10-digit	11-digit	
	50242-917-01	50242-0917-01	1200 mg/20 mL single-dose vial
	50242-918-01	50242-0918-01	840 mg/14 mL single-dose vial
Administration procedures: CPT	96413		Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
	96415		Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
	96417		Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

*The JZ modifier is required on claims for all single-dose containers or single-use drugs when no drug is discarded/administered to any patient as of July 1, 2023. For more information on the JZ modifier, visit CMS.gov.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

TECENTRIQ® is a registered trademark of Genentech, Inc.

Please see full Prescribing Information for Important Safety Information.

Genentech
A Member of the Roche Group
© 2026 Genentech, Inc.
All rights reserved. M-US-00020737(v2.0) 05/26